RxDoctor Payments Data

Mahmood Mirbagheri, MD

Internal Medicine · Fountain Valley, CANPI 1952300261

Payments from drug & device makers

$2,470in general payments, 2019–2025

Across 29 payments — averaging $85.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$972
  • AstraZeneca$594
  • Pfizer$243
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$141
  • Gilead$125
  • Amgen$120
  • plus $276 from 4 others

What the payments were for

  • Food & beverage$2,470100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,470 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$67,960
Medicare patients
217
Services billed
561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$48,426
XareltoRivaroxaban17$8,907
JardianceEmpagliflozin14$7,804
EntrestoSacubitril/Valsartan11$6,414
Breo ElliptaFluticasone/Vilanterol15$6,181
Aripiprazole13$2,689
Tamsulosin Hcl91$1,720
Gabapentin70$1,364
Carbidopa-LevodopaCarbidopa/Levodopa14$1,317
Mirtazapine34$1,193
Atorvastatin Calcium88$1,146
Quetiapine Fumarate96$1,141
Lisinopril56$959
Albuterol Sulfate HfaAlbuterol Sulfate27$885
Furosemide173$830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$243$48,42675 claims
Johnson & JohnsonXarelto$972$8,90717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →